Bonito Biosciences and DaltonTx announce AI-driven collaboration to advance precision delivery for oligotherapeutics
- Collaboration combines Bonito's proprietary functional delivery data engine and ligand discovery platform with DaltonTx's adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS.
Bonito Biosciences ("Bonito"), a biotechnology company building the data foundation for programmable oligotherapeutic delivery, and DaltonTx, the intelligence backbone for modern drug discovery connecting AI, human expertise and experimental data, today announced a collaboration to advance next-generation precision delivery systems for Bonito's oligotherapeutic medicines.
The collaboration will initially focus on delivery to the central nervous system (CNS), combining Bonito's proprietary functional delivery data engine and ligand discovery platform with DaltonTx's adaptive AI systems to iteratively model, predict and optimize precision delivery biology. Together, the companies will work to identify, optimize and advance delivery ligands for conjugated oligotherapeutic payloads, including novel bispecific approaches for targeted CNS delivery.
Through its functional selection platform, Bonito screens hundreds of billions of encoded ligands against complex cellular delivery phenotypes. These powerful datasets — physically generated and directly tested on cell systems of interest — capture high-dimensional information related to receptor engagement and cellular delivery.
DaltonTx will apply its adaptive AI systems to model these data and accelerate the design and optimization of next-generation delivery ligands through structural prediction, affinity mapping and developability analysis. Together, the companies aim to establish an iterative learning loop for the rapid discovery of precision delivery systems for conjugated oligotherapeutics.
"This collaboration brings together two highly complementary capabilities: Bonito's ability to generate uniquely rich functional delivery data at massive scale and DaltonTx's deep expertise in adaptive AI systems for molecular design and optimization. We believe precision delivery is fundamentally a data and prediction problem. By combining closed-loop functional screening with AI-driven design, we aim to accelerate the discovery of delivery systems capable of reaching tissues and cell types that have historically remained inaccessible to oligotherapeutics."
— Richard Wagner, CEO, Bonito Biosciences
"AI systems are only as powerful as the quality and dimensionality of the underlying biological data. Bonito has built a uniquely differentiated platform for generating functional delivery datasets at extraordinary scale. Combining these data with DaltonTx's world-leading agentic AI platform, which integrates AI, human expertise, and experimental data into one continuous learning engine, has the potential to significantly accelerate the discovery of next-generation delivery systems for conjugated oligotherapeutics."
— Dr. Garry Pairaudeau, CEO and Co-Founder, DaltonTx
About Bonito Biosciences
Bonito Biosciences is building the data foundation for programmable oligotherapeutic delivery. The company combines giga-scale encoded ligand libraries, functional cellular selections and AI-driven learning systems to generate proprietary datasets linking molecular structure to delivery function across tissues and cell types. Bonito is leveraging these capabilities to discover next-generation delivery ligands and develop precision oligotherapeutics designed to reach historically inaccessible biological targets.
About DaltonTx
DaltonTx is building the collaborative intelligence backbone for modern drug discovery, fusing agentic AI, human expertise, and wet-lab experimentation into one continuously learning engine. By unifying data, models, and experimental results — all of which have historically been siloed and fragmented — DaltonTx's platform learns in real time, looping experimental evidence back into a refinement cycle of unprecedented velocity.
DaltonTx captures what worked, what failed and why, with full context and perfect memory, so judgement compounds over time. Agents propose strategies, evaluate trade-offs, and autonomously execute computational workflows; experiments are prioritised for maximum learning, with new data fed back immediately, while human scientists set direction and interpret what the system uncovers.
The outcome is smarter decisions, fewer wasted experiments, and faster, more confident progress towards better molecules. Customers don't just get better models; they get better judgement. A self-learning system will always outperform one that doesn't. Speed and efficiency emerge naturally, but they are by-products, not the goal — the true breakthrough is smarter decision-making, and the confidence to tackle more complex biology, knowing that every cycle improves the next choice.
Founded on research from the University of Oxford and built by leaders with decades of experience behind AI discovery platforms at AstraZeneca and Exscientia, DaltonTx delivers reliable, secure, enterprise-quality engineering — high-performance, scalable infrastructure that is readily deployed. Delivered as a secure, modular, plug-and-play cloud platform, DaltonTx integrates in days, not months, with no heavy IT lift.
For more information please contact
Bonito Biosciences
Dan Rosmarin, Head of BD & Corporate Strategy
Email: drosmarin@bonitobio.com
Optimum Strategic Communications
Nick Bastin, Eleanor Cooper, Henry Williams
Tel: +44 20 4604 4016
Email: daltontx@optimumcomms.com